Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger Authors: Brittany Peterson, William Nguyen, Laminou Maliki Haroun, Farissatou Oumarou, Ahmed M. Arzika, Ramatou Maliki, Abdou Amza, Karamba Alio, Nasser Gallo, Bawa Aichatou, Ismael Issa Sara, Diallo Beidi, James G. Kahn, Stefano M. Bertozzi, Elodie Lebas, Benjamin F. Arnold, Thomas M. Lietman, Kieran S. O’Brien, Meagan C. Fitzpatrick, the AVENIR Study Group, Abraham Flaxman, Abraham Flaxman, Abraham Flaxman Published: 2026 ABSTRACT As programs for azithromycin mass drug administration (AZ-MDA) to reduce child mortality have begun in some parts of West Africa, it is imperative to understand their financial costs. We combined a micro-costing framework and observations from an implementation-focused sub-study within the AVENIR trials in 80 communities in the Dosso region of Niger to estimate the national health sector financial costs of a scaled-up programmatic approach for azithromycin biannual distribution to children aged 1–59 months of age living in nonurban areas, using the door-to-door modality. Our outcomes of interest were the annual budget at the regional and national levels for Niger and the cost per dose delivered. We found that the annual national budget required for AZ-MDA achieving 90% average coverage would be $12.5 million (M) (95% Uncertainty Interval (UI) $12.2M, $13.0M) translating to $1.59 (95% UI $1.40, $2.30) per dose delivered. Across regions, cost per dose would vary from $1.17 (95% UI $1.03, $1.69) to $3.61 (95% UI $3.20, $5.16), with higher cost per dose expected for more sparsely populated regions. Training costs represented a large fraction (16.4%) of total costs, and integration of training with that for existing health interventions may provide opportunities for efficiency. Introduction Under-5 mortality (U5MR) in the West and Central Africa region remains much higher than United Nations Sustainable Development Goal 2030 targets [1–3]. The region reports 95 deaths per 1000 live births in 2019, which is 19 times higher than the U5MR reported in high income settings [1,2]. Azithromycin mass drug administration (AZ-MDA) is one effective approach to reduce child mortality. The Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance trial (MORDOR) found that biannual distribution of oral azithromycin to children 1–59 months old reduced mortality by 14% in Malawi, Niger, and Tanzania after 2 years, with longer-term follow-up confirming these findings [4–6]. In 2020, the World Health Organization released conditional guidelines suggesting this intervention be considered in some high mortality settings in sub-Saharan Africa [7]. Recently, the AVENIR (Azithromycine pour la Vie des Enfants au Niger: Implementation et Recherche) trial in Niger confirmed the intervention effectiveness observed during MORDOR, leading to plans for broad roll-out of AZ-MDA in Niger, Mali, Nigeria, and potentially elsewhere [8,9]. MORDOR and follow-up studies were resource-intensive and relied on dedicated study teams for azithromycin distribution. However, programmatic implementation will ultimately occur within existing health systems and must be affordable. Our team conducted a cluster-randomized trial to evaluate programmatic approaches for a standalone AZ-MDA that relied on community health workers (CHWs), comparing door-to-door and fixed-point delivery across several indicators, including reach, costs, fidelity, and acceptability at multiple stakeholder levels [10]. The study found that although the door-to-door delivery modality had slightly higher costs, it also resulted in a greater number of doses delivered and was therefore more efficient (i.e., had a lower cost per dose). The World Health Organization has estimated the cost of mass drug administration (MDA) for neglected tropical diseases to be less than $0.50 USD per person per year [11]. However, one systematic review of 34 studies evaluating the cost of MDA against neglected tropical disease found broad variation in on-the-ground costs [12]. Within these 34 studies, 90% of MDA programs that included cost effectiveness analyses used local volunteer time, which provides financial savings but may compromise program coverage or reach [12]. In Niger, the use of volunteers for MDA is not common practice as payment ensures quality of work and availability of CHWs so all CHWs involved in MDA are paid for their time. In a regression model, the review found that the financial cost more than doubles when using paid health workers [12–14]. Furthermore, economies of scale were important, with less populated areas incurring a higher cost per dose. For instance, an MDA targeting trachoma control in remote areas of South Sudan cost $1.50 USD per person treated [15]. Given the focus on non-urban areas for azithromycin, the use of paid CHWs, and currency inflation since the date of the review, we anticipate that the commonly-cited estimate of $0.50 per dose might substantially underestimate the financial resources required for AZ-MDA in Niger. Confirming this heterogeneity, a recent review of costs for community health care worker programs found a range spanning from $0.02 to $482 per beneficiary [16]. The objective of this analysis was to use data from AVENIR to consider the budgetary implications at the regional and national levels as well as the cost per dose of azithromycin mass distribution to improve child survival. As effectiveness results become available from AZ-MDA demonstration projects in the region, this service delivery efficiency information will be crucial for policymakers contemplating program design and scale. Methods The AVENIR project included several studies on azithromycin mass distribution to improve child survival in Niger [8, 9]. The AVENIR Delivery I trial compared door-to-door and fixed point delivery. Because the door-to-door modality reached more children at a lower cost per child, it is the focus of our current study. Details regarding Delivery I trial design, ethics and oversight, interventions, adverse events specification, and data collection are reported in a linked paper [10]. Briefly, trial approval was obtained from the Institutional Review Boards at the Niger Ministry of Health (Comité Nationale Éthique pour la Recherche en Santé) and the University of California, San Francisco. Trial recruitment began in November 2020. For the community level, local leaders provided verbal consent; at the individual level, caregivers provided written consent for children 30–42 days old and verbal consent for older children. The trial was registered at clinicaltrials.gov (NCT04774991). We conducted this analysis from the perspective of the government health sector, specifically the Ministère de la Santé Publique (Ministry of Health) in Niger. We focused on financial costs, although we also do a sensitivity analysis to evaluate elements that carry a non-financial economic burden. We extracted the majority of cost data from the delivery trial expenditure records, with exceptions detailed below. Operational costs likely to represent ongoing program costs were included, and research-specific costs were excluded, based on expenditure records and as necessary consultations with the local team. Specifically, the research-specific expenditures that were excluded and deemed unnecessary for national implementation comprised wages for the post-distribution survey team, per diem for the medical consultant, and the costs of stringent drug monitoring, the latter being necessary for the concurrent mortality trial but unlikely to be implemented in a real-world MDA. We estimated costs for a single calendar year that includes two rounds of drug distribution. We report costs in 2025 USD. As the Delivery I trial was conducted in 2021, we first updated all costs in West Africa CFA except CHW wages using the local inflation rate over that time [17]. CHW wages were not inflated as they are standardized in Niger and have not changed since 2021. Costs were then converted from West African CFA at a commercial exchange rate of 561.88 CFA per USD [18]. We report cost outcomes at three scales: national, regional, and per dose delivered. AZ-MDA programs delivery twice-yearly treatments of a single dose per child at each time point [9]. The target population for the national program is children aged 1–59 months living in non-urban communities with populations of less than 2,500, following the eligibility criteria of the overall AVENIR project for trial purposes. Population census data from the Niger government for 2021 were used to determine number of children 1–59 months in each region [19]. The 2021 census data did not include breakdown by community so we used 2012 data [20] for community number and size as that was the most recent collection of these data. Due to contradicting trends of population growth with depopulation of rural areas since 2012, we could not confidently update the number of eligible communities. For our primary analysis we assumed 90% coverage with two doses annually, based on coverage achieved in the AVENIR Delivery I trial [10]. The number of Centres de Santé Integré (CSIs, primary health care centers) and districts in Niger was received from the Nigerien District Health Information System (DHIS) using data from 2021. Cost per dose was calculated as the estimated budget for a single year divided by the number of doses delivered across two rounds of MDA. Cost estimation and categorization We conducted a micro-costing exercise, which calculated the anticipated annual cost of a national program by summing costs associated with each programmatic activity. In most instances, costs were based on recorded expenditures from the trial for personnel, equipment, training, and supplies. These costs were validated through discussions with the local financial team, review of logged receipts for items, and verification by team members. When records or receipts were not available, the team provided local informed estimation, for instance by going to the market to record the current value of a good. While the AVENIR Delivery I trial occurred alongside a larger randomized clinical trial, costs were estimated as if the program would be a standalone implementation. Therefore, some central costs that were shared between the Delivery I trial and the larger clinical trial were included at their full rate for this estimation. For instance, the budget team served both programs but is represented as fully dedicated to implementation in this estimation. We report costs in five activity categories: distribution; training; central administration; drug transport and storage; and monitoring and evaluation. Distribution includes equipment and personnel needed for community entry and delivering the drug to children. Training costs were estimated at the district and CSI levels. Central costs encompass administration of the program at national, regional, and district levels. Drug transport and storage costs encompass delivering the drug to communities, as well as drug quality control. The cost of the drug itself is omitted from the base case, as it was donated from Pfizer and continued donation is planned; as a scenario analysis we include purchase and international shipping. Monitoring and evaluation are activities such as a pregnancy history and sample collection for antimicrobial resistance monitoring to ensure quality and safety. Personnel and equipment costs related to azithromycin distribution to children (“distribution costs”) were based on expenditures and unit prices observed during the distribution which are detailed in the supplemental material. Distribution costs included two rounds of drug delivery per year. For personnel, we estimated that at least one CHW would be deployed per community, with additional CHW estimated at one per 500 population for communities larger than 500. This reflects operational plans by the Nigerien Ministry of Health. However, CHW are not always available in every community to participate in the MDA. To cover 26% of the CHW needs in AVENIR Delivery I distribution, a CHW was hired from a neighboring district to conduct the MDA. In these instances, a local mobilizer or guide was also hired to facilitate the door-to-door delivery. This extra expense is partially offset by reduced training costs, as the external CHW will have already received training in their own community. Personnel are compensated via per diems. Village and CSI chiefs are given one per diem payment per round, and mobiliser/guides, case agents from the CSI, and CHWs receive per diem for two days of working per round (S1 Table). CHWs are given a transportation per diem once per round regardless of how many villages they visit. CSI chiefs are given a communication per diem once per round. Backpacks and dosing poles are provided once per year. Hand sanitizer is given to every CHW at each round. Mineral water is used to reconstitute the azithromycin powder for oral suspension, and the number of 500 mL bottles needed was estimated using an average 3.6 doses per bottle of azithromycin and 32 bottles of azithromycin diluted per bottle of mineral water. Water bottles are used over the country’s water supply to ensure safe, clean water is used for treatment delivery. Syringes are needed for infants under one year of age and calculated as one per infant per round. Dosing cups are used for children one year and older and are included in the drug shipments at no additional cost. Sensitization activities to communicate and educate about the MDA program are also included as distribution costs. A sensitization occurs before every MDA distribution. The first sensitization of the year occurs at the district level, with national, regional, district, CSI, and community level representatives all being compensated for their time and provided with refreshments. A radio program similar public communications also occur as a yearly expense. The second MDA distribution involves a smaller scale sensitization that just includes CSI and community leaders being compensated for their time. Mapping exercises are also conducted annually in order to update information on eligible communities and plan operations, for which participants are compensated for their time. Regional estimates for distribution costs reflect the application of costs for a single child, community, or CSI across their region-specific counts. Training costs include those related to the entire cascade in a training-of-trainers model, where district and CSI leaders received training one day, and then provided training to the CHWs under their jurisdiction on another day. Each level of training took a single day. The first level of training occurred in each district and included a national supervisor who was given a per diem and a room rental. District chiefs were provided with a communication budget to coordinate the training, as well as a per diem, meals and coffee. A district communicator was also given a budget for communicating to the CSI chiefs about attendance. CSI chiefs were provided with per diem, transportation costs, communication budget, meals, and coffee. On the second day of training, CSI chiefs trained the CHWs, as well as case agents from the CSI. CSI chiefs were provided with a per diem, meals, and coffee. Case agents were given per diem, meals and coffee, as well as a transportation budget. CHWs received the same plus notebooks and pens. As some CHWs will cover more than one community (see paragraph above), we calculated the number of CHWs attending training as 74% of the estimate if all CHW were working in their home community. Training occurs prior to each round, as there can be substantial turnover in healthcare professionals, and also as a refresher for personnel who have previously been engaged in azithromycin distribution. Central costs were first estimated for each level of health administration (national, regional, and district), then multiplied by the count of administrative units at each level. The national scale up is run by the same non-profit organization, Centre de Recherche et Interventions en Santé Publique (CRISP), that ran the trial so these costs will remain the same as in the trial. These counts were based on 2012 census data (RENALOC) and 2021 DHIS data (Table 1). For costs at the national level, costs were split evenly between all regions. All central costs were calculated by multiplying the observed unit cost by the quantity needed annually. Total counts of geographic information including number of districts, CSIs, population numbers, and numbers of CHWs for each geographic level. 10.1371/journal.pgph.0006039.t001Table 1Geographic information of Niger.RegionCSIDistrictsUnder 5 populationNon-urban communitiesSmall grappes < 200 populationCHWs (per-capita scenario)CHWs (2 relais scenario) Dosso 1838557,7394,9192,6234,7227,281 Tahoua 26613905,6314,1301,3454,7796,113 Maradi 2099922,8285,4201,6546,2278,022 Zinder 21911961,4258,4143,9298,12612,453 Tillaberi 27813739,6616,0112,4906,0148,897 Agadez 947127,2471,2167659971,800 Diffa 726155,0092,6321,9422,1243,896 National 1,321674,369,54032,74214,47832,98948,462 Geographic information of Niger. Drug transportation and storage costs were provided via quotes from the Niger National Office for Pharmaceutical and Chemical Products (ONPPC). The cost of drug reception, inventory, and transportation to every CSI was given as a flat cost specific to each region. The cost of quality control, which includes verification of the volume, quantity, label, and chemical composition of one bottle per lot, for each treatment was estimated as a per-lot cost. We estimated that a national program would require 10 lots per distribution. The cost for drug storage was given as a rate per cubic meter per month, with each cubic meter holding one pallet of drugs containing 3,840 bottles. The number of pallets needed was estimated using the number of doses required per region, assuming each bottle would give 3.6 doses, and rounded up to whole pallets per region. These costs were then summed at the regional and national levels. The category of monitoring and evaluation includes the cost of surveillance for antimicrobial resistance (AMR) as well as mortality through pregnancy history data collection. In this case, we departed from micro-costing and estimated the fraction of the overall AVENIR expenditures that were dedicated to AMR monitoring, then applied this fraction as a multiplier on the estimated budget for all other activities. AMR monitoring costs comprised 5% of total AVENIR expenditures, so we included it in the budget as 5% of the cost total for all other categories. Similarly, we included mortality monitoring cost in the same way, as 5% of the total cost for all other categories, not including (or including) AMR monitoring costs. Sensitization activities to educate and communicate with leaders regarding these data collections are also included in mortality and evaluation costs. We were also interested in “cross-cutting categories” of the fraction of expenditure that would be spent on transportation, education, information, and communication. Transportation costs include CHW transportation for distribution, transportation for all groups (CHWs, case agents, and CSI chiefs) for training, vehicle cost, maintenance, and driver salaries for central costs, as well as cost to bring treatment to CSIs (labeled as drug transport). Education, information, and communication costs include communication costs for CSI chiefs during distribution, district chief and CSI chief communication costs during training, and sensitization costs for AZ-MDA. Scenario analysis The AVENIR Delivery I trial deployed two CHWs per community for each distribution. With upcoming healthcare system reforms, nationwide implementation may instead assign a number of CHWs based on size of the community. We’ve included a comparison of costs from these two scenarios to see how the decision of how many CHWs to use will impact the costs. The primary scenario assumes one CHW distributing azithromycin per 500 population in each community, rounded up. The second scenario assumes two CHWs distributing azithromycin per community regardless of community size. In both analyses, we specified that 26% of the CHW would come from a neighboring community, as described above. Quantities for equipment specific to an individual CHW are also adjusted as the number of distinct CHW changes. Although the rebalancing of personnel modeled for Scenario 1 may improve coverage compared to Scenario 2, we did not have empirical data to support different coverage between these scenarios. To address uncertainty regarding the exact procedures for national AZ-MDA implementation in Niger, we analyzed six programmatic scenarios to determine their impact on the overall budget and the percent change in cost. These include: changing the coverage (to 80% and 100%); including drug price at lower ($0.40 per dose) and higher ($0.70 per dose) benchmarks derived from regional REACH data on landed cost in order to represent replacement cost in the absence of continued drug donation (personal correspondence, D. Call); removing notebooks and pens for the CHWs during training; reducing the percentage of central administrator salaries paid at the regional and district level to 50% as their time may be shared with other programs; reducing CHW training costs by 50% as the training time may be shortened or consolidated with other programs; and varying the percentage of communities with local CHWs available to work during the distribution. Sensitivity analysis We conducted a series of one-way sensitivity analyses to identify the budget areas where a change would have the most dramatic budget impact. We separated costs into more volatile and less volatile and tested a 50% increase or decrease compared to baseline for more volatile groups, and a 25% increase or decrease for less volatile groups. More volatile groups included cost of fuel for vehicles, vehicle costs, and drug transport and storage costs; these were deemed more volatile due to occasional shortages in the region [21]. Less volatile groups included the per diem given to workers involved in training and distribution; equipment needed for distribution; salaries of central administrators; and communication costs used during training. We propagated uncertainty surrounding our empirical observations of CHW availability and program coverage into Uncertainty Intervals (UI) surrounding our base case estimate. No line item costs were influenced by both sources of uncertainty simultaneously, therefore each UI component was calculated independently and applied to the relevant cost items. The number of CHWs available in each community varies, which determines the number of mobilizer/guides needed. To determine the bounds for number of mobilizer/guides needed, the 95% confidence interval for proportion of mobilizers was calculated using a Beta distribution with shape parameters α = 20 and β = 58 using 200 simluated draws to simulate uncertainty centered around the 26% mobilizer use seen in AVENIR Delivery I [10]. Another factor that influences the uncertainty interval is the treatment coverage. Costs that are influenced by treatment coverage include the number of bottles of mineral water and syringes needed for distribution, as well the cost for storage of drug. The cost per dose is also influenced, as the number of doses delivered in the denominator is dependent on coverage. To determine 95% confidence interval bounds for treatment coverage, treatment coverages at the community level seen in AVENIR Delivery I for the door-to-door modality at Round 2 was used, capping treatment coverages at 100%. Across all relevant cost items, the lower and upper bounds of the UI were then calculated by applying the corresponding lower and upper bound of the relevant uncertainty source, either the simulated mobilizer proportion interval or the empirically-driven coverage interval, to that item’s cost calculation. Results The national budget for one year of biannual azithromycin distribution to treat children aged 1–59 months in Niger is estimated to be $12.50 million (M) (95% UI $12.22M – $13.04M) (Table 2). Regional costs vary from $777 thousand (K) (95% UI $768K– $794K) in Agadez to $2.71M (95% UI $2.64M – $2.83M) in Zinder, which are also the least and most populous regions, respectively. Nationally, there are an estimated 4,369,540 children eligible for treatment (Table 1). The national average cost per dose delivered at a treatment coverage of 90% is $1.59 (95% UI $1.40 – $2.30) (Table 2). Across regions, the cost per dose ranges from $1.17 (95% UI $1.03 – $1.69; Tahoua) to $3.61 (95% UI $3.20 – $5.16; Diffa), differing due to different population sizes and number of districts and/or CSIs. 10.1371/journal.pgph.0006039.t002Table 2Number of doses delivered, overall costs, and cost per dose of the MDA program by category.Cost TypeDossoEstimate(95% UI)TahouaEstimate(95% UI)MaradiEstimate(95% UI)ZinderEstimate(95% UI)TillaberiEstimate(95% UI)AgadezEstimate(95% UI)DiffaEstimate(95% UI)NationalEstimate(95% UI)Number of Doses1,003,930(725,061, 1,115,478)1,630,136 (1,177,320, 1,811,262)1,661,090 (1,199,676, 1,845,656)1,730,565 (1,249,853, 1,922,850)1,331,390 (961,559, 1,479,322)229,045 (165,421, 254,494)279,016 (201,512, 310,018)7,865,172 (5,680,402, 8,739,080) Distribution Overall cost$870,334 ($846,357, $906,395)$851,239 ($823,659, $882,296)$1,067,483 ($1,034,426, $1,106,573)$1,462,351 ($1,421,954, $1,512,042)$1,105,443 ($1,074,953, $1,142,646)$224,645 ($218,527, $231,848)$437,113 ($426,588, $450,631)$6,018,609 ($5,846,464, $6,232,430)Cost per Dose*$0.87($0.76, $1.25)$0.52($0.45, $0.75)$0.64($0.56, $0.92)$0.85($0.74, $1.21)$0.83($0.73, $1.19)$0.98($0.86, $1.40)$1.57($1.38, $2.24)$0.77($0.67, $1.10) Training Overall cost$291,651 ($285,487, $328,631)$315,229 ($308,990, $352,661)$373,298 ($365,170, $422,067)$469,546 ($458,939, $533,189)$387,651 ($379,801, $434,751)$82,736 ($81,435, $90,537)$129,536 ($126,763, $146,171)$2,049,647 ($2,006,586, $2,308,007)Cost per dose*$0.29($0.26, $0.45)$0.19($0.17, $0.30)$0.22($0.20, $0.35)$0.27($0.24, $0.43)$0.29($0.26, $0.45)$0.36($0.32, $0.55)$0.46($0.41, $0.73)$0.26($0.23, $0.41) Central Overall cost$362,380 ($362,380, $362,380)$512,794 ($512,794, $512,794)$392,463 ($392,463, $392,463)$452,628 ($452,628, $452,628)$512,794 ($512,794, $512,794)$332,297 ($332,297, $332,297)$302,214 ($302,214, $302,214)$2,867,571 ($2,867,571, $2,867,571)Cost per dose*$0.36($0.32, $0.50)$0.31($0.28, $0.44)$0.24($0.21, $0.33)$0.26($0.24, $0.36)$0.39($0.35, $0.53)$1.45($1.31, $2.01)$1.08($0.97, $1.50)$0.36($0.33, $0.50) Drug Transport Overall cost$32,055($27,305, $33,955)$57,210($49,609, $60,535)$66,027 ($57,951, $69,115)$75,827 ($67,514, $79,153)$84,875 ($78,462, $87,488)$66,760 ($65,573, $67,236)$46,396 ($44,971, $46,871)$429,151 ($391,386, $444,352)Cost per dose*$0.03($0.02, $0.05)$0.04($0.03, $0.05)$0.04($0.03, $0.06)$0.04($0.04, $0.06)$0.06($0.05, $0.09)$0.29($0.26, $0.41)$0.17($0.15, $0.23)$0.05($0.04, $0.08) Monitoring Overall cost$155,642 ($152,153, $163,136)$173,647 ($169,505, $180,829)$189,927 ($185,001, $199,022)$246,035 ($240,104, $257,701)$209,076 ($204,601, $217,768)$70,644 ($69,783, $72,192)$91,526 ($90,054, $94,589)$1,136,498 ($1,111,201, $1,185,236)Cost per dose*$0.16($0.14, $0.22)$0.11($0.09, $0.15)$0.11($0.10, $0.17)$0.14($0.12, $0.21)$0.16($0.14, $0.23)$0.31($0.27, $0.44)$0.33($0.29, $0.47)$0.14($0.13, $0.21) Overall Overall cost$1,712,062 ($1,673,682, $1,794,497)$1,910,119 ($1,864,557, $1,989,114)$2,089,198 ($2,035,011, $2,189,239)$2,706,389 ($2,641,140, $2,834,713)$2,299,839 ($2,250,612, $2,395,447)$777,083 ($767,615, $794,110)$1,006,786 ($990,590, $1,040,476)$12,501,475 ($12,223,207, $13,037,596)Cost per dose*$1.71($1.50, $2.47)$1.17($1.03, $1.69)$1.26($1.10, $1.82)$1.56($1.37, $2.27)$1.73($1.52, $2.49)$3.39($3.02, $4.80)$3.61($3.20, $5.16)$1.59($1.40, $2.30)* cost per dose indicates the cost of one of the twice yearly AZ-MDA treatments Number of doses delivered, overall costs, and cost per dose of the MDA program by category. * cost per dose indicates the cost of one of the twice yearly AZ-MDA treatments Costs by category Distribution costs comprise the largest fraction of the budget, both nationally and in every region except Agadez (Table 2). The national distribution cost is estimated to be $6.02M (95% UI $5.85M – $6.23M), which is 48.1% of the total budget. Regional distribution costs vary, from $225K (95% UI $219K – $232K) (Agadez) to $1.46M (95% UI $1.42M – $1.51M) (Zinder). Distribution costs by item are shown in S1 Table. The cost of two rounds of training during one year for azithromycin distribution nationally is estimated to be $2.05M (95% UI $2.01M, $2.31M) (Table 2). Regional costs vary, from $83K (95% UI $81K – $91K) (Agadez) to $470K (95% UI $459K – $533K) (Zinder). Training costs by item are shown in S2 Table. The total drug transport and cold chain storage cost nationally is estimated to be $429K (95% UI $391K - $444K) with regional costs varying from $32K (95% UI $27K - $34K) (Dosso) to $85K (95% UI $78K - $87K) (Tillaberi) (Table 2). The main driver of cost in this category is the distance of the region from the national capital of Niamey. S3 Table shows drug transport and cold chain storage cost by item. The total central cost nationally is estimated to be $2.87M with regional costs varying from $302K (Diffa) to $513K (Tahoua and Tillaberi) (Table 2). Central costs are largely driven by the number of districts in each region, as district personnel are compensated at numerous points during AZ-MDA. We captured no uncertainty in central costs. Central costs by item are shown in S4 Table. The total monitoring cost nationally is estimated to be $1.14M (95% UI $1.11M - $1.19M) with regional costs varying from $71K (95% UI $70K - $72K) in Agadez, to $246K (95% UI $240K - $257K) in Zinder. Monitoring & evaluation costs are shown in S5 Table. Nationally, 17.5% (95% UI 17.3% - 18.6%) of the total budget is spent on transportation, and 14.5% (no variance to create an uncertainty interval) on education, information, and communication (S6 Table). Scenario analysis We compared costs when assignment of CHW is based on community population size (Scenario 1) against assignment of two CHW per community regardless of population size (Scenario 2) (Fig 1, S1 Fig). Nationally, assigning the number of CHWs based on community size has 13.2% lower overall cost compared to Scenario 2, with reduced costs specifically during distribution (19.5% lower than Scenario 2) and training (11.9% lower than Scenario 2). The reduced cost for Scenario 1 arises due to many small communities being assigned only one CHW to deliver the drug, which is not offset by populous eligible communities being assigned additional CHW. Comparison of costs between two scenarios regarding number of CHWs used in distribution. Differences in shading indicate different cost types. Costs are in 2021 USD. Six other scenario analyses were conducted (Table 3, Fig 2). First, adjusting treatment coverage to 80% (compared to 90% in the main analysis) decreased the total budget by $36K (0.29%) and increased the cost per dose by $0.19 (12.0%). Adjusted treatment coverage to 100% increased the total budget by 35K (0.28%) and decreased the cost per dose by $0.16 (10.0%). 10.1371/journal.pgph.0006039.t003Table 3Scenario analyses including new total budget, cost per dose, and percent changes for each scenario.ScenarioNew Total BudgetNew Cost per DoseBudgetPercent ChangeCost per DosePercent Change Change in coverage 80% coverage$12,465,751-0.3%$1.7812.0%100% coverage$12,536,9380.3%$1.43-10.0% Add Drug Cost Low-end $0.40 per dose$17,179,11037.4%$2.1837.2%High-end $0.70 per dose$20,703,48965.6%$2.6365.5% Relais Receive Half-day Training $11,462,357-8.3%$1.46-8.1% Remove Notebooks & Pens $12,264,118-1.9%$1.56-1.9% Central Administrators at 50% Time $10,924,311-12.6%$1.39-12.5% Change in Mobilizer Use No Mobilizer Use$13,290,4416.3%$1.696.3%50% Mobilizer Use$11,773,199-5.8%$1.50-5.6% Scenario analyses including new total budget, cost per dose, and percent changes for each scenario. Comparison of costs between scenario analyses. Differences in shading indicate different cost types. The cost per dose for drug procurement is estimated to be between $0.40 and $0.70 per dose. Including this cost would increase the total budget by $468K (37.4%) to $820K (65.6%). The cost per dose would increase by $0.59 (37.2%) to $1.04 (65.5%) over costs without drug procurement (Table 3). In our base case reflecting the AVENIR Delivery I trial, CHWs would be given a full day of training dedicated to AZ-MDA. However, CHW training may be able to integrate with other programs in the future. Under a scenario where training for CHWs was limited to only half a day, the national budget decreased by $104K (8.3%) and the cost per dose by $0.13 (8.1%) (Table 3). In another potential training modification, implementing teams may choose not to provide pens and notebooks to CHW during training, particularly if training for AZ-MDA is consolidated with training for other programs. Removing these notebooks and pens would decrease the national budget by $237K (1.9%) and decrease the cost per dose by $0.03 (1.9%) (Table 3). In our base case we assumed that there would be central administrators dedicating 100% of their time to this program. However, there is the possibility that these administrators could split their time between this program and others, particularly once the program has been established. To determine the financial impact of this reduced effort, we considered a scenario with regional and district administrators giving 50% of their time to this program, with national administrators remained fully dedicated to AZ-MDA. This change decreased the overall budget by $1.58M (12.6%) and the cost per dose by $0.20 (12.5%) (Table 3). In our final scenario analysis, we varied the percentage of CHW personnel need that is able to be filled by a local CHW, with the remainder requiring a mobilizer/guide for accompaniment. Our base case incorporated the observation that 74% of the required personnel needs in AVENIR Delivery I trial were filled by CHWs who reside in the communities they are serving. As AZ-MDA expands beyond the original regions served, this number could change. We varied this percentage from 0 to 100% in intervals of 10% (Table 3, S1 Fig), finding that the overall cost decreases as CHWs are shared across communities. This reduction is largely driven by need to train fewer CHWs. Sensitivity analysis To identify the types of expenditures whose cost variation might have the greatest impact on the total budget, we examined changes, both negative and positive, in per diem rates, salaries, equipment, vehicles, fuel, drug transport & storage, and communication (Fig 3). A 25% change in per diem would result in the largest change to the national budget at $846K. Adjustment to vehicle costs and fuel charges by 50% would also bring substantial changes at $349K and $242K, respectively. A 25% change to salary would impact overall cost by $233K. Similarly, a 25% change to equipment costs would bring about a $217K impact. Adjusting drug transport costs by 25% would have a $176K impact. Finally, a 25% change in communication costs would have the smallest budgetary impact at just $9K. Tornado plot showing the impact of change in selected cost types on the annual national budget for AZ-MDA with low volatility costs with 25% change in blue-scale and high volatility costs with 50% change in orange-scale. Discussion Implementing an AZ-MDA that faithfully replicated the processes used in the AVENIR trials including all rural eligible communities in Niger would cost an estimated $12.50M (95% UI $12.22M - $13.04M) per year, corresponding to $1.59 (95% UI $1.40 - $2.30) cost per dose. We previously published an analysis of training and delivery costs for the AVENIR Delivery I trial, resulting in $1.91 per dose for those categories alone [10]. However, given the smaller scale of the trial, it is consistent with expectations that it would be less cost-efficient than a national program. Our cost per dose is higher than found in a previous meta-analysis of MDA against neglected tropical diseases, which pooled evidence from 56 costing studies to confirm a benchmark of $0.50 per dose ($0.67 per dose in 2025 dollars) [12]. As noted, AZ-MDA in Niger does not rely on volunteer time, thus raising the financial cost of the program when compared to the benchmark cost. By contrast, volunteer time carries a substantial economic cost, not included within the meta-analysis benchmark due to limited reporting in the original papers. Although our study also does not capture non-financial economic costs, these are likely a small addition in our case, as few elements of the program currently involve in-kind donations (aside from the drug, whose price is reported) and the house-to-house delivery minimizes household economic burden. Additionally, the meta-analysis identified that cost per dose in rural areas is higher than in urban areas due to the smaller population reached for a similar amount of resources. The AZ-MDA program we model for Niger specifically targets rural communities. In fact, community size emerges as one of the major drivers of subnational variation in cost per dose for this analysis. When there are many communities with small populations (less than 200 people), we see the cost per dose rise dramatically. For instance, such small communities are over 70% of all eligible communities in Diffa, the most expensive district per dose delivered, compared with less than 1/3 of all eligible communities in Tahoua, the least expensive per dose delivered. This relationship is driven by the fact that each community requires the same activities such as a CHW visit, sensitization, and education – even if there are only a small number of children present as the denominator across which expenses can be spread. Similarly, the ratio between district supervisory personnel and children is higher when communities are small, driving up central costs. By contrast, children within these small communities may be among those most likely to benefit from AZ-MDA. Small communities are less likely to have their own health center, and there is correlation between distance from a health center and both baseline morality and AZ-MDA effectiveness. Analyses specifically examining the cost-effectiveness of reaching small communities could provide valuable insight for AZ-MDA as well as other rural health programs. This analysis identifies a few potentially feasible programmatic changes that might increase efficiency without sacrificing treatment coverage. Training for AZ-MDA does not require a full day of work and therefore could potentially be integrated with training for a similar program. Similarly, our assumption that there would be central staff entirely dedicated to AZ-MDA may not reflect reality. If both training and central administration were shared equally with another program, the overall cost could be reduced by up to 20%. However, it may not be easy to identify another program with shared training timing and underutilized central personnel. We recognize as well that this well-funded implementation trial included a high level of supervision, and a long-term program may not choose to sustain this; although this would very likely result in coverage declines. Easier targets such as eliminating branded notebooks and pens do not provide substantial savings and may come with the tradeoff of decreased morale or motivation. While these costs can be decrease in case programs face budget shortfalls, monitoring and evaluation costs should remain in place. These monitoring costs may be the first to be dropped, however it’s crucial that these activities be kept in place to monitor mortality and AMR. At 5% of the budget, these costs would not provide considerable savings if dropped and are important to be kept in place. Similarly, our finding that costs are reduced by relying on a smaller cadre of trained CHW accompanied by a larger number of mobilizers might not be an actionable way to achieve savings, if perceived as the deliberate exclusion of trained CHW who reside in a community. Instead, this scenario analysis should be interpreted as a reassurance that there are not negative financial consequences when trained CHWs from neighboring communities are teamed up with mobilizers, as additional distribution expenses are offset by reduced training needs. A strength of this study is that costs relating to drug distribution and personnel training came from a closely monitored trial. We were able to gather all costs as they occurred, and minimal assumptions were necessary regarding wages, per diems, and market prices. Other costs that weren’t observed within the AVENIR trial such as costs for drug transport and storage came directly from the government of Niger. Therefore, the unit costs included in this budget adhere closely to reality in Niger. One limitation of our study was uncertainty regarding population size and distribution, as we had to synthesize data sources from different years. Specifically, we calculated the number of CHWs needed in each community based on community population size from 2012 census data, while our costs, number of children under 5 years old, and other geographic information was captured in 2021. There have likely been population changes between 2012 and 2021, however we were not confident making assumptions regarding these changes for rural Niger. Although the national population is growing, it is possible that rural populations are declining due to urbanization trends, so constant growth seemed indefensible. With our costing analytic structure in place, we hope to be able to update the analysis when more recent population data become available. Another potential limitation is that while we removed all trial expenditures not applicable to a national program, there may be residual costs included here that differ from the reality of programmatic implementation. While this is a possibility, we believe our detailed monitoring of costs allowed us to parse trial specific costs from real-world implementation costs with good fidelity. Across West Africa, trials have been underway to evaluate the impact of azithromycin when delivered in diverse settings and integrated with a variety of platforms [9, 22–25]. The AVENIR trial confirmed azithromycin effectiveness when delivered to children 1–59 months of age, although not when restricted to 1–11 months of age [9]. Other settings evaluating delivery to only 1–11 months of age have thus far seen no statistically significant effectiveness [26, 27]. Therefore, the expanded age range is likely to be the model for countries considering azithromycin to improve child survival. The MOH in Niger has begun nationwide implementation of AZ-MDA which makes the current analysis extremely salient. Stopping guidelines for the national AZ-MDA program in Niger have been defined by the MOH in Niger, and AVENIR II is currently testing these stopping guidelines [28]. The cost of drug procurement was not included in our base case as the drug is currently being donated by Pfizer, and is continuing to be donated in the national implementation in Niger. As actual expenses from the national program become available, this micro-costing exercise is intended to serve as a source of insight into the drivers of regional differences as well as sources of financial risk. Although other countries will have different population sizes, wage structures, and operational considerations, the costs detailed here can hopefully support informed decisions regarding the deployment of all-to-scarce resources to improve child health and survival in Niger and beyond. Supporting information Stacked bar graph of percentage cost breakdown. (PDF) Price per percent of CHW capacity. (PDF) Distribution costs by item. (PDF) Training costs by item. (PDF) Drug transport and cold chain storage costs by item. (PDF) Central costs by item. (PDF) Monitoring costs by item. (PDF) Cross-cutting costs. (PDF) 24 Mar 2026 PGPH-D-26-00439 Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger PLOS Global Public Health Dear Dr. Fitzpatrick, Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 23 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Abraham D. Flaxman, Ph.D. Academic Editor PLOS Global Public Health Journal Requirements: 1. Please provide a detailed online Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published. a) State the initials, alongside each funding source, of each author to receive each grant. For example: “This work was supported by the National Institutes of Health (####### to AM; ###### to CJ) and the National Science Foundation (###### to AM).” b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” For more information, please go to our submission guidelines: https://journals.plos.org/globalpublichealth/s/submission-guidelines#loc-financial-disclosure-statement 2. Please ensure that the funders and grant numbers match between the Financial Disclosure field and the Funding Information tab in your submission form. Note that the funders must be provided in the same order in both places as well. 3. Please update your online Competing Interests statement. If you have no competing interests to declare, please state: "The authors have declared that no competing interests exist." 4. Please provide separate main figure files in .tif or .eps format only and ensure that all files are under our size limit of 10MB. For more information about how to convert your figure files please see our guidelines: https://journals.plos.org/globalpublichealth/s/figures 5. We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files before or after the references list. 6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 7. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments (if provided): [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously?--> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: This is a detailed evaluation of the costs of azithromycin MDA. The methodology is sound and the paper is well written. The discussion of economies of scale is particularly strong and timely. I have the following minor comments: • The fact that you are focusing on financial costs should be more clearly reflected in the abstract. • Since economic costs (rather than financial costs) are typically considered the standard in full economic evaluations, this distinction in cost types (and the implications) should be discussed more explicitly in the Discussion section, ideally as a dedicated paragraph. • It would be helpful to include references in the Methods for the assumed cost per dose of azithromycin. • The Sensitivity Analysis section in the Results feels a little brief and could be expanded slightly. • The majority of cost data were extracted from delivery trial expenditure records. Were any research costs excluded? Trials often differ from programmatic delivery, and this should be acknowledged as a potential limitation in the Discussion. • It is great to see the 95% uncertainty intervals on the costs. It would be helpful to expand the Methods section to describe exactly how these were calculated. Currently, the abbreviation “UI” is only spelled out in the abstract. • Regarding the sentence: “Our cost per dose is higher than found in a previous meta-analysis of MDA against neglected tropical diseases, which identified a benchmark of $0.50 per dose ($0.67 per dose in 2025 dollars).” I do not believe (apologies if I’m wrong) that this study identified this benchmark — it was already commonly used. I suggest double checking the references and wording around the US$0.50 benchmark. • Figure 1 – please check the axis labels. • Clearly define that you are using K for thousands and M for millions when presenting costs in the text. • State the method used to adjust for inflation in more detail (e.g., use of local vs. US inflation rates) Reviewer #2: Review of Research Article PGPH-D-26-00439 Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger The manuscript describes a study to estimate the cost of implementing azithromycin mass drug administration for child survival in Niger. The study will be helpful to Niger and other countries considering this intervention. The manuscript is well written, the acquisition of cost data is thorough, and the analyses are appropriate for the research questions. A few comments are below. Major: In the first paragraph of the Results section and again in the first paragraph of the Discussion, the authors write about cost per dose. This was slightly confusing as the treatment regimen in Niger (and elsewhere) calls for double dose to children in fairly close succession. Therefore, to understand the true cost of this treatment regimen, does the dose cost need to be doubled? Or does the $1.59 represent a “treatment cost per person”? Please do clarify this in the Methods and possibly with a footnote for Table 2. In the discussion section the authors describe M&E activities such as AMR monitoring that they expect programs to continue to implement during programmatic implementation of the MDA regimen. They also include these costs in their overall estimate. It seems that this type of monitoring (as well as the QC monitoring of drug supply, for example) may be the first to be dropped if and when programs face budget shortfalls. In the Discussion, the authors should consider pointing out the importance of these activities, and maybe demonstrate that compared to most other activities, dropping this monitoring would not provide considerable savings (if that is the case). The Discussion would be strengthened if the authors discussed the number one factor that affected costs per table 3 and Figure 2, the cost of purchasing the medication. Readers would benefit from learning the current status of the donation program and official commitments from Pfizer. Have end-line outcomes been developed to know when a child survival program, and thus a drug donation, may cease in these settings? If the timeline is likely long, and the cost go up considerably if there is donation, is this a serious threat to the long-term viability of this intervention? Minor Abstract-line 44-define mass drug administration as MDA the first time it is used. Line 107-108 should use AZ-MDA. Line 149-150 was based on the assumption from the trial- is the assumption 90% with each dose or that 90% of children do get both doses? Line 200-please list the size of the bottle of water (in ml). I wonder if it will be common for countries to purchase such large quantities of bottled water? Wouldn’t some countries likely rely on their water supply with iodine or boiling if needed? Line 201-202 are cups used for those over ages 1 year? Line 387-is there a font change in this sentence? ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public. For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] --> -->-->Figure Resubmissions: -->-->While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.-->--> After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.--> 7 May 2026 Submitted filename: Response to Reviewers.docx 31 May 2026 Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger PGPH-D-26-00439R1 Dear Dr Fitzpatrick, We are pleased to inform you that your manuscript 'Micro-costing for national-scale azithromycin mass drug administration to improve child survival in Niger' has been provisionally accepted for publication in PLOS Global Public Health. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health. Best regards, Abraham D. Flaxman, Ph.D. Academic Editor PLOS Global Public Health *********************************************************** Reviewer Comments (if any, and for reference): Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** -->2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously?--> Reviewer #1: N/A Reviewer #2: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: My comments have been addressed Reviewer #2: (No Response) ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public. For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No **********